Dynavax Technologies Corporation - Common Stock (DVAX)

Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been fundamentally reshaped. Sanofi (NASDAQ: SNY) announced yesterday, December 24, 2025, that it has entered into a definitive agreement to acquire Dynavax Technologies (NASDAQ: DVAX) for approximately $2.2 [...]

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ: SNY), the French healthcare titan that has spent the last five years shedding its image as a slow-moving legacy conglomerate to emerge as a [...]

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the French healthcare titan that has spent the last five years aggressively shedding its legacy skin, has punctuated its transformation with the $2.2 billion acquisition of Dynavax Technologies [...]

Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax Technologies (NASDAQ: DVAX) in an all-cash transaction valued at approximately $2.2 billion. The announcement triggered a 39% surge in Dynavax shares, thrusting the Emeryville-based vaccine specialist into [...]

A healthcare titan wants to buy the biotech's vaccines.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge follows the official announcement that global pharmaceutical giant Sanofi (NASDAQ:SNY) has entered into a definitive agreement to acquire

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

French drugmaker Sanofi agreed to acquire vaccine maker Dynavax in a $2.2 billion deal.

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session.

Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.

Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.